{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:50:17Z","timestamp":1778687417780,"version":"3.51.4"},"reference-count":64,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1904,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1111\/j.1478-3231.2010.02292.x","type":"journal-article","created":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T02:51:31Z","timestamp":1276656691000},"page":"1427-1438","source":"Crossref","is-referenced-by-count":26,"title":["Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion"],"prefix":"10.1111","volume":"30","author":[{"given":"Pei-Jer","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Hyub","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Yeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HanLim","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shukui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Long","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ee-Min","family":"Yeoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,6,15]]},"reference":[{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB1|cit1","first-page":"2137","article-title":"Patterns of cancer incidence, mortality, and prevalence across five continents","volume":"24","author":"Kamangar","year":"2006","journal-title":"defining priorities to reduce cancer disparities in different geographic regions of the world"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1440-1746.2009.05784.x","article-title":"Asia pacific working party on prevention of hepatocellular carcinoma. Hepatocellular carcinoma in the Asia pacific region","volume":"24","author":"Yuen","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Panel of experts in HCC-design clinical trials. Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB5|cit5","first-page":"1129","volume-title":"DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology","author":"Bartlett","year":"2008"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB6|cit6","first-page":"55","article-title":"Geographic difference in survival outcome for advanced hepatocellular carcinoma","volume":"31","author":"Hsu","year":"2010","journal-title":"implications on future clinical trial design"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02292.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000173419","article-title":"For the organizing commmittee of the Japan-Korea liver symposium (JKLS). Epidemiology of hepatocellular carcinoma in Japan and Korea","volume":"75","author":"Kim","year":"2008","journal-title":"Oncology"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02292.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1111\/j.1872-034X.2007.00171.x","article-title":"Liver cancer in Korea","volume":"37","author":"Han","year":"2007","journal-title":"Hepatol Res"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB9|cit9","first-page":"879","article-title":"Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer","volume":"27","author":"Luk","year":"2007","journal-title":"from laboratory discovery to clinical evaluation"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB10|cit10","first-page":"1111","article-title":"Management of hepatocellular carcinoma in Asia","volume":"10","author":"Poon","year":"2009","journal-title":"consensus statement from the Asian oncology summit 2009"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(81)90585-7","article-title":"Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan","volume":"2","author":"Beasley","year":"1981","journal-title":"Lancet"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/j.ejca.2006.06.007","article-title":"Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis","volume":"42","author":"Chen","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1572-0241.2006.00364.x","article-title":"for the Italian liver cancer (ITA.LI.CA) group. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma","volume":"101","author":"Cantarini","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2004.05.161","article-title":"Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy","volume":"22","author":"Yeo","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB15|cit15","first-page":"28","article-title":"Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients","volume":"28","author":"Martyak","year":"2008","journal-title":"a meta-analysis"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB16|cit16","first-page":"519","article-title":"Systematic review","volume":"148","author":"Loomba","year":"2008","journal-title":"the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.21024","article-title":"A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization","volume":"43","author":"Jang","year":"2006","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1245\/s10434-009-0694-z","article-title":"A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection","volume":"17","author":"Li","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1440-1746.2006.04707.x","article-title":"Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma","volume":"22","author":"Kuzuya","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2169\/internalmedicine.48.1534","article-title":"Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function","volume":"48","author":"Koda","year":"2009","journal-title":"Intern Med"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/bjs.6731","article-title":"Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis","volume":"96","author":"Breitenstein","year":"2009","journal-title":"Br J Surg"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB22|cit22","first-page":"889","article-title":"Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC)","volume":"52","author":"Shen","year":"2010","journal-title":"a meta-regression approach"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/B978-0-443-06694-8.50088-9","volume-title":"Abeloff's Clinical Oncology","author":"Weber","year":"2008"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB24|cit24","first-page":"1425","article-title":"Hepatocellular carcinoma","volume":"12","author":"O'Neil","year":"2007","journal-title":"the role of the north American GI steering committee hepatobiliary task force and the advent of effective drug therapy"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB25|cit25","first-page":"395","article-title":"Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma","volume":"24","author":"Ueno","year":"2002","journal-title":"a validation analysis"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB26|cit26","unstructured":"National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: hepatobiliary cancers. v.2.2009 National Comprehensive Cancer Network http:\/\/www.nccn.org"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB27|cit27","first-page":"2650","article-title":"Validation of clinical AJCC\/UICC TNM staging system for hepatocellular carcinoma","volume":"120","author":"Kee","year":"2007","journal-title":"analysis of 5,613 cases from a medical center in southern Taiwan"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB28|cit28","first-page":"1760","article-title":"Construction of the Chinese university prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the cancer of the liver Italian program staging system","volume":"94","author":"Leung","year":"2002","journal-title":"a study based on 926 patients"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB29|cit29","first-page":"324","article-title":"The criteria of clinical diagnosis and staging of primary liver cancer","volume":"12","author":"Chinese Society of Liver Cancer.","year":"2001","journal-title":"Chin J Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB30|cit30","first-page":"502","article-title":"Prognostic indicators in hepatocellular carcinoma","volume":"29","author":"Tandon","year":"2009","journal-title":"a systematic review of 72 studies"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02292.x-BIB31|cit31","article-title":"Prognostic system for hepatitis B virus (HBV)-related hepatocellular carcinoma- prospective validation of the Chinese university prognostic index","volume":"26","author":"Yeo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB32|cit32","first-page":"1208","article-title":"AASLD practice guideline","volume":"42","author":"Bruix","year":"2005","journal-title":"management of hepatocellular carcinoma"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB33|cit33","unstructured":"Japan Society of Hepatology. http:\/\/www.jsh.or.jp\/english\/02-Contents.pdf"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3350\/kjhep.2009.15.3.391","article-title":"Practice guidelines for management of hepatocellular carcinoma 2009","volume":"15","author":"Korean Liver Cancer Study Group and National Cancer Center.","year":"2009","journal-title":"Korean J Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB35|cit35","first-page":"322","article-title":"Liver transplant in Asia","volume":"38","author":"Ng","year":"2009","journal-title":"past, present and future"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02292.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1111\/j.1872-034X.2007.00167.x","article-title":"Review of the 4th single topic conference on HCC","volume":"37","author":"Kudo","year":"2007","journal-title":"Hepatol Res"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02292.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1111\/j.1872-034X.2007.00168.x","article-title":"Epidemiology of hepatocellular carcinoma in USA","volume":"37","author":"El-Serag","year":"2007","journal-title":"Hepatol Res"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB38|cit38","first-page":"240","article-title":"Ten-year experience with liver transplantation at Queen Mary Hospital","volume":"8","author":"Lo","year":"2002","journal-title":"retrospective study"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/cncr.22759","article-title":"Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma","volume":"110","author":"Park","year":"2007","journal-title":"Cancer"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cncr.23684","article-title":"Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis","volume":"113","author":"Han","year":"2008","journal-title":"Cancer"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB41|cit41","first-page":"111","article-title":"Review article","volume":"12","author":"Mathurin","year":"1998","journal-title":"overview of medical treatments in unresectable hepatocellular carcinoma - an impossible meta-analysis?"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"For the SHARP investigators study group. Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB43|cit43","first-page":"25","article-title":"Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma","volume":"10","author":"Cheng","year":"2009","journal-title":"a phase III randomised, double-blind, placebo-controlled trial"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB44|cit44","article-title":"Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC)","volume":"26","author":"Zhu","year":"2008","journal-title":"insights from a multidisciplinary phase II study"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB45|cit45","author":"Faivre","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02292.x-BIB46|cit46","article-title":"Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC)","author":"Koeberle","journal-title":"a multicenter phase II trial (SAKK 77\/06 and SASL 23)"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB47|cit47","unstructured":"Hoda D Catherine C Strosberg J et al"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02292.x-BIB48|cit48","article-title":"An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC)","author":"Raoul","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB49|cit49","unstructured":"Finn RS Kang Y Park J et al"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1359-6349(09)71239-X","article-title":"International phase 2 trial of ABT-869 in patients with advanced hepatocellular carcinoma (HCC)","volume":"7","author":"Toh","year":"2009","journal-title":"Eur J Cancer Suppl"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB51|cit51","unstructured":"Hsu C Yang TS Huo TL et al http:\/\/ex2.excerptamedica.com\/CIW-09ecco\/index.cfm?fuseaction=CIS2002&hoofdnav=Abstracts&content=abs.details&what=AUTHOR&searchtext=hsu&topicselected=*&selection=ABSTRACT&qryStartRowDetail=7"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02292.x-BIB52|cit52","article-title":"A phase I study of pazopanib in patients with advanced hepatocellular carcinoma","author":"Yau","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB53|cit53","unstructured":"Govindarajan R Siegel ER Makhoul I Williamson SK."},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2008.18.3301","article-title":"Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma","volume":"27","author":"Thomas","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl.)","key":"10.1111\/j.1478-3231.2010.02292.x-BIB55|cit55","article-title":"Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC)","author":"Kaseb","journal-title":"J Clin Oncol"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02292.x-BIB56|cit56","first-page":"1","article-title":"Hepatocellular carcinoma 2009 and beyond","volume":"75","author":"Kudo","year":"2008","journal-title":"from the surveillance to molecular targeted therapy"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB57|cit57","first-page":"62","article-title":"Natural history of untreated nonsurgical hepatocellular carcinoma","volume":"29","author":"Llovet","year":"1999","journal-title":"rational for the design and evaluation of therapeutic trials"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB58|cit58","first-page":"429","article-title":"Systemic review of randomized trials for unresectable hepatocellular carcinoma","volume":"37","author":"Llovet","year":"2003","journal-title":"chemoembolization improves survival"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/j.1572-0241.2005.00229.x","article-title":"Natural history of untreated nonsurgical hepatocellular carcinoma","volume":"100","author":"Yeung","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1349-7006.2007.00648.x","article-title":"Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma","volume":"99","author":"Furuse","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000173432","article-title":"Systemic chemotherapy of hepatocellular carcinoma - Korean experience","volume":"75","author":"Lee","year":"2008","journal-title":"Oncology"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-009-1096-4","article-title":"UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib","volume":"65","author":"Meza-Junco","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference. European association for the study of the liver","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02292.x-BIB64|cit64","first-page":"7","article-title":"Progression-free survival as surrogate and as true end point","volume":"21","author":"Saad","year":"2010","journal-title":"insights from the breast and colorectal cancer literature"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2010.02292.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1478-3231.2010.02292.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:16:14Z","timestamp":1740183374000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2010.02292.x"}},"subtitle":["HCC clinical trials in Asia"],"short-title":[],"issued":{"date-parts":[[2010,6,15]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2010.02292.x","relation":{},"ISSN":["1478-3223"],"issn-type":[{"value":"1478-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6,15]]}}}